Prostaglandin E1 and F2alpha specific binding in bovine corpora lutea: comparison with luteolytic effects.
Preliminary characterization indicated the presence of separate prostaglandin (PG)E1 and (PG)F2alpha binding sites in membrane fractions prepared from bovine corpora lutea. These differ in the rate and temperature dependence of the specific binding. Equilibrium binding data indicate the apparent dissociation constants as 1.32 x 10(-9)M and 1.1 x 10(-8)M for PGE1 and PGF2alpha, respectively. Competition of several natural prostaglandins for the PGE1 and PGF2alpha bovine luteal specific binding sites indicates specificity for the 9-keto or 9alpha-hydroxyl moiety, respectively. Differences in relative ability to inhibit 3H-PG binding were found due to sensitivity to the absence or presence of the 5, 6-cis-double bond as well. Bovine luteal function was affected following treatment of heifers with 25 mg PGF2alpha as measured by reduced estrous cycle length, decreased corpus luteum size and significantly decreased plasma progesterone levels. In contract, treatment with 25 mg PGE1 resulted in cycle lengths comparable to those of non-treated herdmates with no apparent modification in corpus luteum size. However, plasma progesterone levels were increased significantly following PGE1 treatment compared to pretreatment values. In so far as data obtained in vitro on PGF2alpha relative binding affinity to the bovine CL can be compared to data obtained independently in vitro on PGF2alpha induced luteolysis in the bovine, PGF2alpha relative binding to the CL and luteolysis appeared to be associated. By similar reasoning, there was no apparent relationship between PGE1 relative binding affinity in the luteal fractions and luteolysis in estrous cyclic cattle.
D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D002417:Cattle; D003338:Corpus Luteum / Q000187:drug effects / Q000378:metabolism*; D004971:Estrus / Q000187:drug effects; D005260:Female; D008186:Luteolytic Agents / Q000378:metabolism* / Q000494:pharmacology; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011453:Prostaglandins / Q000378:metabolism; D011454:Prostaglandins A / Q000378:metabolism; D011458:Prostaglandins E / Q000378:metabolism* / Q000494:pharmacology; D011460:Prostaglandins F / Q000378:metabolism* / Q000494:pharmacology; D011955:Receptors, Drug; D013997:Time Factors
D008186:Luteolytic Agents; D011453:Prostaglandins; D011454:Prostaglandins A; D011458:Prostaglandins E; D011460:Prostaglandins F; D011955:Receptors, Drug; D011374:Progesterone